Literature DB >> 11569701

Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.

M Romero-Gómez1, F Boza, M S García-Valdecasas, E García, J Aguilar-Reina.   

Abstract

OBJECTIVES: In patients with compensated liver cirrhosis the clinical repercussions of detecting subclinical hepatic encephalopathy (SHE) are unclear. We present a long-term follow-up study in cirrhotic patients to examine the relationship between SHE and subsequent episodes of overt hepatic encephalopathy.
METHODS: A total of 63 cirrhotic patients were studied by Number Connection Test and auditory evoked potentials. We determined glutamine, ammonia, zinc, glutamate, urea, and ratio of branched chain amino acids to aromatic amino acids, and Child-Pugh classification.
RESULTS: Of 63 patients, 34 (53%) exhibited SHE. Nineteen out of 63 (30%) developed overt hepatic encephalopathy during follow-up. Hepatic encephalopathy in follow-up was related to alcoholic etiology, ammonia, glutamine, zinc, ratio of branched chain amino acids to aromatic amino acids, liver function, presence of esophageal varices, and detection of SHE (84% of patients who exhibited hepatic encephalopathy in follow-up showed SHE). In Cox-regression, glutamine levels, SHE, esophageal varices, and Child-Pugh class were the independent variables related to hepatic encephalopathy in follow-up.
CONCLUSIONS: SHE (defined on the basis of number connection test or auditory evoked potentials alteration) could predict a subsequent episode of overt hepatic encephalopathy. Lower glutamine levels, presence of esophageal varices, and liver dysfunction were also related to the development of overt hepatic encephalopathy.

Entities:  

Mesh:

Year:  2001        PMID: 11569701     DOI: 10.1111/j.1572-0241.2001.04130.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  105 in total

1.  Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis.

Authors:  Henry H Nguyen; Mark G Swain; Philip Wong; Stephen E Congly
Journal:  CMAJ Open       Date:  2018-12-03

2.  Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy.

Authors:  Vicente Felipo; Amparo Urios; Encarna Montesinos; Inmaculada Molina; Maria L Garcia-Torres; Miguel Civera; Juan A Del Olmo; Joaquin Ortega; Jose Martinez-Valls; Miguel A Serra; Norberto Cassinello; Abdallah Wassel; Esperanza Jordá; Carmina Montoliu
Journal:  Metab Brain Dis       Date:  2011-11-10       Impact factor: 3.584

3.  The Treatment of Patients With Hepatic Encephalopathy: Review of the Latest Data from EASL 2010.

Authors:  Kevin D Mullen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-07

4.  Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver.

Authors:  Radha K Dhiman; Roshan Kurmi; Kiran K Thumburu; Sunil H Venkataramarao; Ritesh Agarwal; Ajay Duseja; Yogesh Chawla
Journal:  Dig Dis Sci       Date:  2010-05-28       Impact factor: 3.199

Review 5.  Neurophysiological investigation of hepatic encephalopathy.

Authors:  Piero Amodio; Angelo Gatta
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

Review 6.  The extrahepatic consequences of cirrhosis.

Authors:  Jin Kee Ho; Eric Yoshida
Journal:  MedGenMed       Date:  2006-03-02

Review 7.  Disaccharides in the treatment of hepatic encephalopathy.

Authors:  Praveen Sharma; Barjesh Chander Sharma
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

8.  Management of hepatic encephalopathy.

Authors:  Jennifer A Frontera
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

9.  Pannexin1 as a novel cerebral target in pathogenesis of hepatic encephalopathy.

Authors:  Papia Mondal; Surendra Kumar Trigun
Journal:  Metab Brain Dis       Date:  2014-05-08       Impact factor: 3.584

10.  Driving Performance Among Patients with Cirrhosis Who Drove to Their Outpatient Hepatology Clinic Appointments.

Authors:  Paul J Thuluvath; Anantha Nuthalapati; Jennifer Price; Anurag Maheshwari
Journal:  J Clin Exp Hepatol       Date:  2015-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.